Exploratory research on effectiveness and safety of Rituximab treatment including maintenance administration for steroid intractable autoimmune bullous diseases of the skin. Rtx-BD Trial (Rituximab of Intractable Autoimmune Bullous Disease Trial) 2
Phase 1
Completed
- Conditions
- Pemphigus, Pemphigoid
- Registration Number
- JPRN-UMIN000015451
- Lead Sponsor
- Department of Dermatology, Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pregnancy 2) Allergy for biologics 3) Severe organ disorder 4) History of other diseases which need systemic steroid treatment 5) Infections 6) Malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) A rate of severe adverse events, beyond CTCAE grade 3. 2) A rate of remission
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Rituximab's efficacy in steroid-resistant pemphigus and pemphigoid?
How does maintenance Rituximab compare to standard-of-care therapies in autoimmune bullous disease management?
Which biomarkers correlate with response to anti-CD20 therapy in intractable pemphigus and pemphigoid patients?
What adverse events are associated with long-term Rituximab use in autoimmune skin disease treatment?
Are there combination therapies with anti-CD20 agents for steroid intractable pemphigus and pemphigoid?